Phosphodiesterase type 5 inhibitors for pulmonary arterial hypertension.
Archer
Stephen L
SL
Section of Cardiology, Department of Medicine, University of Chicago, Chicago, IL 60637, USA. sarcher@medicine.bsd.uchicago.edu
Michelakis
Evangelos D
ED
D000925:Anticoagulants / Q000627:therapeutic use; D004232:Diuretics / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D004417:Dyspnea / Q000209:etiology; D005260:Female; D006801:Humans; D006976:Hypertension, Pulmonary / Q000188:drug therapy* / Q000209:etiology / Q000503:physiopathology; D008875:Middle Aged; D058986:Phosphodiesterase 5 Inhibitors; D010726:Phosphodiesterase Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D010879:Piperazines / Q000009:adverse effects / Q000627:therapeutic use*; D017410:Practice Guidelines as Topic; D011687:Purines / Q000009:adverse effects / Q000627:therapeutic use; D000068677:Sildenafil Citrate; D013450:Sulfones / Q000009:adverse effects / Q000627:therapeutic use*; D014859:Warfarin / Q000627:therapeutic use
D000925:Anticoagulants; D004232:Diuretics; D058986:Phosphodiesterase 5 Inhibitors; D010726:Phosphodiesterase Inhibitors; D010879:Piperazines; D011687:Purines; D013450:Sulfones; D014859:Warfarin; D000068677:Sildenafil Citrate